loading
前日終値:
$73.40
開ける:
$73.3
24時間の取引高:
675.77K
Relative Volume:
0.41
時価総額:
$7.66B
収益:
$628.56M
当期純損益:
$141.82M
株価収益率:
55.73
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-8.38%
1か月 パフォーマンス:
-9.31%
6か月 パフォーマンス:
+39.59%
1年 パフォーマンス:
+115.30%
1日の値動き範囲:
Value
$69.50
$73.80
1週間の範囲:
Value
$69.50
$77.16
52週間の値動き範囲:
Value
$29.42
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
名前
Corcept Therapeutics Inc
Name
セクター
Healthcare (1175)
Name
電話
650.688.8803
Name
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
職員
500
Name
Twitter
Name
次回の収益日
2025-02-17
Name
最新のSEC提出書
Name
CORT's Discussions on Twitter

CORT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
70.37 7.66B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.89 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.55 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.82 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
550.91 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.00 28.51B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-11-06 アップグレード Truist Hold → Buy
2023-04-11 開始されました SVB Securities Market Perform
2023-04-04 開始されました Piper Sandler Overweight
2023-02-15 ダウングレード Jefferies Buy → Hold
2022-08-01 ダウングレード Truist Buy → Hold
2022-07-27 アップグレード Jefferies Hold → Buy
2022-06-27 再開されました Canaccord Genuity Buy
2022-02-02 開始されました Canaccord Genuity Buy
2022-01-28 開始されました Truist Buy
2020-08-05 ダウングレード Jefferies Buy → Hold
2019-09-24 開始されました Jefferies Buy
2019-09-06 開始されました H.C. Wainwright Buy
2019-02-04 ダウングレード B. Riley FBR Buy → Neutral
2018-08-10 繰り返されました Stifel Hold
2018-05-31 ダウングレード Stifel Buy → Hold
2018-03-09 開始されました B. Riley FBR, Inc. Buy
2017-08-31 開始されました Stifel Buy
2017-02-02 開始されました Ladenburg Thalmann Buy
2015-04-21 開始されました FBR Capital Outperform
2014-01-13 ダウングレード Stifel Buy → Hold
2013-08-09 ダウングレード Janney Buy → Neutral
2013-08-09 ダウングレード Ladenburg Thalmann Buy → Neutral
2012-02-21 繰り返されました JMP Securities Mkt Outperform
2010-01-06 アップグレード Ladenburg Thalmann Neutral → Buy
2008-07-17 開始されました Rodman & Renshaw Mkt Outperform
2007-06-21 アップグレード Punk, Ziegel & Co Mkt Perform → Accumulate
すべてを表示

Corcept Therapeutics Inc (CORT) 最新ニュース

pulisher
Jun 16, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada

Jun 16, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News

Jun 11, 2025
pulisher
Jun 06, 2025

Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive

Jun 06, 2025
pulisher
Jun 06, 2025

Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics (CORT) Reports Promising Survival Data in A - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting | CORT Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics (CORT) Reports Promising Survival Data in ALS Study | CORT Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 04, 2025

Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy Rating - Insider Monkey

Jun 04, 2025
pulisher
Jun 03, 2025

ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Yahoo

Jun 03, 2025
pulisher
Jun 02, 2025

Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Relacorilant shows promise for ovarian cancer treatment By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Therapeutics (CORT) Shows Positive Phase 3 Trial Results for Ovarian Cancer Treatment | CORT Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept shares rise on positive Phase 3 trial results By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept shares rise on positive Phase 3 trial results - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Relacorilant shows promise for ovarian cancer treatment - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jun 02, 2025
pulisher
Jun 02, 2025

Zacks Research Issues Pessimistic Outlook for CORT Earnings - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga

May 30, 2025
pulisher
May 30, 2025

Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World

May 30, 2025
pulisher
May 30, 2025

Equities Analysts Offer Predictions for CORT Q1 Earnings - Defense World

May 30, 2025
pulisher
May 29, 2025

Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

May 29, 2025
pulisher
May 28, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World

May 28, 2025
pulisher
May 23, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World

May 23, 2025
pulisher
May 22, 2025

Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com

May 22, 2025
pulisher
May 21, 2025

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent

May 21, 2025
pulisher
May 21, 2025

Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders

May 21, 2025
pulisher
May 21, 2025

Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

May 21, 2025
pulisher
May 19, 2025

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World

May 18, 2025
pulisher
May 15, 2025

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com

May 15, 2025
pulisher
May 14, 2025

Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World

May 14, 2025
pulisher
May 12, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

May 12, 2025
pulisher
May 12, 2025

Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance

May 12, 2025

Corcept Therapeutics Inc (CORT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.82
price up icon 0.65%
$35.68
price down icon 1.00%
$21.46
price up icon 0.75%
$98.32
price down icon 2.32%
$108.74
price up icon 2.15%
biotechnology ONC
$245.00
price up icon 1.29%
大文字化:     |  ボリューム (24 時間):